US20040053423A1 - Immunochromatographic assay method and apparatus - Google Patents

Immunochromatographic assay method and apparatus Download PDF

Info

Publication number
US20040053423A1
US20040053423A1 US10/643,632 US64363203A US2004053423A1 US 20040053423 A1 US20040053423 A1 US 20040053423A1 US 64363203 A US64363203 A US 64363203A US 2004053423 A1 US2004053423 A1 US 2004053423A1
Authority
US
United States
Prior art keywords
membrane
analytical
support member
sample
test strip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/643,632
Inventor
Ronald LaBorde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/643,632 priority Critical patent/US20040053423A1/en
Publication of US20040053423A1 publication Critical patent/US20040053423A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54386Analytical elements
    • G01N33/54387Immunochromatographic test strips
    • G01N33/54388Immunochromatographic test strips based on lateral flow
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/97Test strip or test slide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures

Definitions

  • This invention relates generally to immunoassays, and more specifically to an improved chromatographic assay, often referred to as a lateral flow assay, having a test strip employing susperparamagnetic particles as the labels for the analytes to be detected, where, as an additional feature, the analytical strip is removable for reading the quantity of analytes captured therein and for archival purposes.
  • test strip typically held in a carrier, which may have various configurations.
  • One end of the test strip is exposed to the sample, normally a body fluid of some type, being tested for the particular target analytes of interest.
  • particular analytes are indicative of particular biological, environmental, and biohazard conditions, among others. For example, urine may be tested for pregnancy or ovulation and if the target analytes are present, the test is positive.
  • Body fluids may be tested for the presence of other analytes indicative of biological conditions or they may be indicative of the presence of substances, such as drugs. Another example would be for testing water for contaminates. Examples of lateral flow assay methods and apparatuses, where the reading is normally conducted optically, are shown in U.S. Pat. Nos. 5,591,645; 5,798,273; 5,622,871; 5,602,040; 5,714,389; 5,879,951; 4,632,901; and 5,958,790.
  • optically detected assays There are several limitations or disadvantages to the known optically detected assays. Because they are optical, only surface changes (coloration, typically) can be detected. The target analytes may be in the sample solution but of such a low concentration that only a relatively few are captured in the capture zone in the porous membrane of the assay. This provides a faint or even non-optically detectable line, and a resultant false negative reading. Quantitative assessments are really only an estimation based on color intensity of the detection line. Because the prior art assays are optically read, they are subject to contamination by exposure, and light-caused degradation. Optical assays have a limited archival shelf life.
  • the invention relates to lateral flow immunoassay technology employing superparamagnetic particles as the labels for the analytes to be detected.
  • the bound complexes of labeled particles and analytes are captured in predetermined areas or regions on the test strip and the presence and quantity of labeled analytes are then readable by magnetic means.
  • An advantageous additional feature of the invention is that the test strip can be removable from the support member for archival purposes or for reading by an appropriate magnetic sensing device, or both.
  • a relatively standard lateral flow assay structure is employed but the invention greatly improves the sensitivity of the device over known lateral flow techniques. It provides a very rapid (a few seconds) measurement of the analytical region in the test strip.
  • magnetic particles over known colored particles or other optical indicators in the prior art. These include linearity because magnetic detection is linear with respect to the amount of magnetic material present over a wide range, through at least four orders of magnitude. Time stability is also significant because magnetic particles are stable.
  • the developed assay is available to be archived and retested as necessary. Further, magnetic particles are generally inert to biological systems and the environment so they not only remain stable, they are environmentally and biologically safe. Further, magnetic particles are already in widespread use throughout the diagnostics industry with other technologies so they are readily available. Other benefits of magnetic detection are that since the particles are superparamagnetic, they are magnetic only when in a magnetic field. This allows them to be freely manipulated in solution without aggregating.
  • Another significant advantage over the prior art optical lateral flow devices is that with this invention the total amount of analytes in the capture region of the test strip is measured as a single mass in one volumetric measurement by magnetic means.
  • the permeability of magnetic fields is such that any analyte contained within the active region of the detector will be measured. This contrasts with optical sensing techniques in which only reporter-analyte interactions on or very near the surface are detectable.
  • the strength of the magnetic signal increases directly with the mass of iron involved. This inherent linearity of magnetic detection contributes to sensitivity, accuracy and dynamic range.
  • superparamagnetic particles are physically similar to collodial gold with regard to size, and may be easily adapted to a wide range of lateral flow assays. It is noted that collodial gold, as well as fluorescent latex particles, are typically employed in the prior art optically sensed immunological assay techniques.
  • the sample introduction area conventionally comprising a sample pad and a conjugate pad.
  • the conjugate pad was the source of freely moveable colored particles, typically gold sols from collodial gold, or fluorescent latex particles.
  • the moveable particles are the superparamagnetic particles which label the target analytes from the sample being introduced through the sample pad.
  • the sample, together with the bound magnetic particle labels and target analytes, move with capillary action along the porous membrane and are captured in a predefined location called a capture region or capture zone.
  • An added feature is that typically a wicking pad is mounted on the far end of the porous membrane to enhance the capillary action which drives the flow from the introduction at one end of the porous membrane through the entire length of the membrane.
  • the porous membrane typically is mounted on a relatively rigid support or base member, but in an advantageous embodiment a separation sheet, or adhesive layer, exists between the base member and the porous membrane.
  • a separation sheet or adhesive layer, exists between the base member and the porous membrane.
  • This enables very easy removal of the test strip, which normally would include the separation sheet, so that the test strip is a very thin element which may be magnetically sensed in an appropriate device.
  • the top of the porous member is preferably covered by another protective sheet or membrane which is not transparent. It may be completely opaque.
  • This top sheet may also include pre-printed standards, which are employed for calibrating purposes so that the magnetic detector can be calibrated for each test to ensure complete accuracy.
  • the protective sheet may not be a separate element in some cases, but may only be the upper surface of the membrane properly treated to function as a protective sheet or surface.
  • FIG. 1 is a schematic perspective, partially phantom, view of an embodiment of the invention
  • FIG. 2 is a schematic side view of the FIG. 1 embodiment
  • FIG. 3 is a schematic side view of a preferred embodiment of the invention.
  • FIG. 4 is a top view of the FIG. 3 embodiment
  • FIG. 5 shows how the test strip of FIG. 3 is removed
  • FIG. 6 is a perspective of a reader device used with the assay apparatus of FIG. 1 or 3 ;
  • FIG. 7 schematically shows how the assay strip is read by a magnetic reader device.
  • a relatively rigid assay support membrane 11 serves as a base and provides support for the test strip, which in this embodiment is removable from the support.
  • backing member 12 On top of the support membrane is backing member 12 on which is mounted porous membrane 13 .
  • the backing member is removably adhered to the support, or it may itself be an adhesive layer.
  • capture zone 14 Within the porous membrane is capture zone 14 .
  • the capature zone is formed by striping with antigens or antibodies, for example, as is well known in the art.
  • On top of the porous membrane is non-light transmissive cover or surface 15 .
  • the cover or surface may be considered to be optically opaque, at least to the extent that capture zone indicia would not be visible through cover 15 .
  • the protective membrane may be made of plastic, glass or paper, for example, or any practical combination thereof.
  • a printed standard or calibration line 16 is situated on top of the cover and provides information utilized by the assay reader after the test has been accomplished. This is contemplated to be a magnetic stripe with the information the reader needs.
  • sample pad 17 At the left end, as shown in FIGS. 1 and 2, is sample pad 17 , through which an analyte-containing sample solution 20 is administered to the porous membrane, with analytes 20 A shown in the sample pad.
  • the sample pad may also include conjugate pad 19 which is in communication with the porous membrane.
  • conjugate pad 19 Within the conjugate pad are superparamagnetic beads or particles which are coupled with antibodies, the combination of a bead and an antibody being referred to as a conjugate, a plurality of them being labeled with reference numeral 20 B.
  • conjugates are configured to combine with target analytes in the sample solution in a known manner to create a sandwich assay, well known in the art, where the beads provide labels for the target analytes.
  • Competitive assay techniques also well known in the art, could also be employed.
  • the porous membrane will, as a feature of some embodiments, have a wicking pad 18 at the opposite, or right, end of the test strip. This is a conventional element.
  • the operation of the lateral flow assay is well known.
  • the labeled analytes (in a sandwich assay, for example) move by capillary action from the left to the right as seen in FIG. 1. Labeled analytes are captured in the capture zone where reading of the assay results is accomplished.
  • Wicking pad 18 enhances capillary flow in the porous membrane by “pulling,” or “driving” the fluid through the porous membrane.
  • a typical material from which the porous membrane is made is nitrocellulose.
  • the present embodiment provides greatly enhanced sensitivity and quantitative accuracy because the magnetic labeled analytes in the capture zone are detectable by a suitable magnetic detector to the extent of the target analytes within the entire volume of the capture zone.
  • Additional features may be added, including additional capture zones 14 (two are shown in FIGS. 3 and 5) and additional calibration lines 16 .
  • additional capture zones 14 two are shown in FIGS. 3 and 5
  • additional calibration lines 16 there are four calibration lines, one before and one after each capture zone. There could be several capture zones and equivalent calibration lines.
  • a significant aspect of an embodiment of the invention is the means and manner of magnetically reading the assay.
  • a magnetic reader 21 of the type contemplated is shown in FIG. 6. This employs the technology disclosed in PCT publication WO 99/27369, to determine the presence of target analytes and their quantity.
  • the reader of the present invention is contemplated to be portable, that is, approximately pocket size, so that it is easily employed in the field. It will provide accurate assay readings even under stressful conditions and in poor light.
  • the apparatus of FIG. 6 has a narrow slit opening 22 into which an assay strip can be inserted for reading by electromagnetic means.
  • the analyte quantity may be shown in window 23 , which could be an LED or an LCD screen, for example.
  • Lower electromagnetic head 31 has a top surface 32 on which is mounted detection coil 34 and across which strip 13 / 15 is positioned with capture zone 14 centered over the detection coil.
  • the strip is shown in this example with surface or cover 15 of the strip actually touching the surface of the detection coil. Cover 15 thus protects the delicate structure of the porous membrane during the reading process, as well as long term if the strip is archived.
  • Top magnet 33 is closely adjacent to the opposite side of the strip, having stripping layer 12 thereon.
  • the structure of the electromagnetic head shown in FIG. 7 is generally equivalent to that in reader 21 .
  • test strip is made readily removable from support membrane 11 , and from sample pad 17 and wicking pad 18 .
  • pull tab 24 is secured to cover 15 , which is, in turn, secured to porous membrane 13 .
  • the porous membrane is removably secured to the support by means of a removable backing 12 membrane and secured to the bottom of the porous membrane. It will be noted that the assay is essentially inverted as shown here. The sample could be applied to sample pad 17 with the strip turned over from the position of FIGS. 3 and 5.
  • the conjugate pad 19 and the wicking pad 18 are positioned between support membrane 11 and the peelable strip 12 , 13 , 15 .
  • Element 11 A may be a non-active polymer fill membrane.
  • Sheet or adhesive 12 is readily removable from the surfaces of elements 18 , 19 and 11 A.
  • test strip primarily consisting of the porous membrane and protective surfaces thereof, may be made sufficiently rigid to not need a support membrane. Such a configuration would not need to be stripped from anything.
  • the reader apparatus might have to be modified somewhat to handle the different configuration of the test strip, but the principle of magnetic reading shown in FIG. 7 still applies.
  • FIG. 5 shows how the test strip, comprised of the cover, porous membrane and removable backing, is removed from the support membrane.
  • this removed test strip is typically about 3-12 mm wide, and only about 150-500 ⁇ thick.
  • This strip is easily fed into reader 21 for a digital readout, which may be shown on the screen or printed on paper in any desired form by reader 21 .
  • the exposed test strip is stable and can be archived either before or after being read. Since the superparamagnetic beads are magnetized only during the reading process, the exposed test strip is not subject to degradation. The analytes contained in the capture zone remain there, labeled with the conjugate combination.
  • test strip being slid off the support membrane or peeled off, either manner of removable being physically possible.
  • the opaque surface or cover 15 has several positive functions. Contrary to prior art optical lateral flow assays, where very faint lines can easily be misinterpreted in the field, especially in stressful situations or low light conditions, there is no possibility of misinterpretation of test results with this invention. Optically read assays, especially those visually read, are also subject to operator bias. In the present invention the reader reads the total number of labeled analytes in the capture zone without inherent sources of error as mentioned above. Further, the thickness of the opaque cover precisely positions the porous membrane and thus, the capture zone, with respect to the magnet head and detection coil 34 .
  • test strip actually touches the detection coil, without the protective surface the porous nitrocellulose membrane would be damaged by rubbing across detection coil 34 , thereby possibly producing incorrect or unreliable readings, or both.
  • cover protects against physical damage and environmental contamination as well as providing precise positioning for accurate electromagnetic readings.

Abstract

An immunochromatographic assay employing superparamagnetic particles to lable the target analytes. An opaque cover prevents misinterpretive readings in field situations and provides a protective surface on the porous membrane. Additional features include separability of the test strip from any backing or housing which is configured to support the strip, and that quantitative measurements of the target analytes are easily and accurately made by means of an electromagnetic reader device.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0001]
  • This invention relates generally to immunoassays, and more specifically to an improved chromatographic assay, often referred to as a lateral flow assay, having a test strip employing susperparamagnetic particles as the labels for the analytes to be detected, where, as an additional feature, the analytical strip is removable for reading the quantity of analytes captured therein and for archival purposes. [0002]
  • 2. Discussion of Related Art [0003]
  • Various chromatographic immunoassay techniques have been available for many years. One common aspect of known devices, particularly in the lateral flow technology is that the assay is read visually, that is, by means of one or more optically readable lines on a test strip, typically held in a carrier, which may have various configurations. One end of the test strip is exposed to the sample, normally a body fluid of some type, being tested for the particular target analytes of interest. It is known that particular analytes are indicative of particular biological, environmental, and biohazard conditions, among others. For example, urine may be tested for pregnancy or ovulation and if the target analytes are present, the test is positive. Body fluids may be tested for the presence of other analytes indicative of biological conditions or they may be indicative of the presence of substances, such as drugs. Another example would be for testing water for contaminates. Examples of lateral flow assay methods and apparatuses, where the reading is normally conducted optically, are shown in U.S. Pat. Nos. 5,591,645; 5,798,273; 5,622,871; 5,602,040; 5,714,389; 5,879,951; 4,632,901; and 5,958,790. [0004]
  • A different technology is employed in other types of biological technologies employing magnetic particles or micobeads, sometimes more specifically termed superparamagnetic iron oxide impregnated polymer beads. These beads are employed to bind with the target analytes in the sample being tested and are then typically isolated or separated out magnetically. Once isolation has occurred, other testing may be conducted, including observing particular images, whether directly optically or by means of a camera. Examples of these technologies are disclosed in U.S. Pat. Nos. 3,981,776; 5,395,498; 5,476,796; 5,817,526; and 5,922,284. Another apparatus for detecting target molecules in a liquid phase is shown in U.S. Pat. No. 5,981,297 where magnetizable particles are employed and the output of magnetic field sensors indicates the presence and concentration of target molecules in the sample being tested. Other examples to sense magnetically using physical forces are disclosed in U.S. Pat. Nos. 5,445,970; 5,981,297 and 5,925,573. [0005]
  • There are several limitations or disadvantages to the known optically detected assays. Because they are optical, only surface changes (coloration, typically) can be detected. The target analytes may be in the sample solution but of such a low concentration that only a relatively few are captured in the capture zone in the porous membrane of the assay. This provides a faint or even non-optically detectable line, and a resultant false negative reading. Quantitative assessments are really only an estimation based on color intensity of the detection line. Because the prior art assays are optically read, they are subject to contamination by exposure, and light-caused degradation. Optical assays have a limited archival shelf life. [0006]
  • None of the known prior art employs magnetic particles in conjunction with lateral flow assay technology. [0007]
  • SUMMARY OF THE INVENTION
  • Broadly speaking, the invention relates to lateral flow immunoassay technology employing superparamagnetic particles as the labels for the analytes to be detected. The bound complexes of labeled particles and analytes are captured in predetermined areas or regions on the test strip and the presence and quantity of labeled analytes are then readable by magnetic means. An advantageous additional feature of the invention is that the test strip can be removable from the support member for archival purposes or for reading by an appropriate magnetic sensing device, or both. [0008]
  • A relatively standard lateral flow assay structure is employed but the invention greatly improves the sensitivity of the device over known lateral flow techniques. It provides a very rapid (a few seconds) measurement of the analytical region in the test strip. There are many advantages of using magnetic particles over known colored particles or other optical indicators in the prior art. These include linearity because magnetic detection is linear with respect to the amount of magnetic material present over a wide range, through at least four orders of magnitude. Time stability is also significant because magnetic particles are stable. The developed assay is available to be archived and retested as necessary. Further, magnetic particles are generally inert to biological systems and the environment so they not only remain stable, they are environmentally and biologically safe. Further, magnetic particles are already in widespread use throughout the diagnostics industry with other technologies so they are readily available. Other benefits of magnetic detection are that since the particles are superparamagnetic, they are magnetic only when in a magnetic field. This allows them to be freely manipulated in solution without aggregating. [0009]
  • Another significant advantage over the prior art optical lateral flow devices is that with this invention the total amount of analytes in the capture region of the test strip is measured as a single mass in one volumetric measurement by magnetic means. The permeability of magnetic fields is such that any analyte contained within the active region of the detector will be measured. This contrasts with optical sensing techniques in which only reporter-analyte interactions on or very near the surface are detectable. In this invention the strength of the magnetic signal increases directly with the mass of iron involved. This inherent linearity of magnetic detection contributes to sensitivity, accuracy and dynamic range. Finally, superparamagnetic particles are physically similar to collodial gold with regard to size, and may be easily adapted to a wide range of lateral flow assays. It is noted that collodial gold, as well as fluorescent latex particles, are typically employed in the prior art optically sensed immunological assay techniques. [0010]
  • In lateral flow technology, at one end of the porous membrane (the active part of the test strip) is the sample introduction area conventionally comprising a sample pad and a conjugate pad. In the prior art, the conjugate pad was the source of freely moveable colored particles, typically gold sols from collodial gold, or fluorescent latex particles. In the present invention, the moveable particles are the superparamagnetic particles which label the target analytes from the sample being introduced through the sample pad. The sample, together with the bound magnetic particle labels and target analytes, move with capillary action along the porous membrane and are captured in a predefined location called a capture region or capture zone. There may be more than one capture zone to enable multiplexing, that is, testing for more than one type of analyte at the same time in the same test strip. Excess analytes and the carrying liquid continue to move on through the capture zone to the other end of the porous membrane, sometimes forming a control line or zone separate from the capture zone. An added feature is that typically a wicking pad is mounted on the far end of the porous membrane to enhance the capillary action which drives the flow from the introduction at one end of the porous membrane through the entire length of the membrane. [0011]
  • The porous membrane typically is mounted on a relatively rigid support or base member, but in an advantageous embodiment a separation sheet, or adhesive layer, exists between the base member and the porous membrane. This enables very easy removal of the test strip, which normally would include the separation sheet, so that the test strip is a very thin element which may be magnetically sensed in an appropriate device. Since optical means are not employed and color at the capture zone has no meaning, the top of the porous member is preferably covered by another protective sheet or membrane which is not transparent. It may be completely opaque. This top sheet may also include pre-printed standards, which are employed for calibrating purposes so that the magnetic detector can be calibrated for each test to ensure complete accuracy. The protective sheet may not be a separate element in some cases, but may only be the upper surface of the membrane properly treated to function as a protective sheet or surface.[0012]
  • BRIEF DESCRIPTION OF THE DRAWING
  • The objects, advantages and features of this invention will be more clearly perceived from the following detailed description, when read in conjunction with the accompanying drawing, is which: [0013]
  • FIG. 1 is a schematic perspective, partially phantom, view of an embodiment of the invention; [0014]
  • FIG. 2 is a schematic side view of the FIG. 1 embodiment; [0015]
  • FIG. 3 is a schematic side view of a preferred embodiment of the invention; [0016]
  • FIG. 4 is a top view of the FIG. 3 embodiment; [0017]
  • FIG. 5 shows how the test strip of FIG. 3 is removed; [0018]
  • FIG. 6 is a perspective of a reader device used with the assay apparatus of FIG. 1 or [0019] 3; and
  • FIG. 7 schematically shows how the assay strip is read by a magnetic reader device.[0020]
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • With reference now to the drawing, and more particularly to FIGS. 1 and 2, there is shown an embodiment of the present invention, a lateral flow test strip for an immunochromatographic assay. A relatively rigid [0021] assay support membrane 11 serves as a base and provides support for the test strip, which in this embodiment is removable from the support. On top of the support membrane is backing member 12 on which is mounted porous membrane 13. The backing member is removably adhered to the support, or it may itself be an adhesive layer. Within the porous membrane is capture zone 14. The capature zone is formed by striping with antigens or antibodies, for example, as is well known in the art. On top of the porous membrane is non-light transmissive cover or surface 15. The cover or surface may be considered to be optically opaque, at least to the extent that capture zone indicia would not be visible through cover 15. The protective membrane may be made of plastic, glass or paper, for example, or any practical combination thereof. A printed standard or calibration line 16 is situated on top of the cover and provides information utilized by the assay reader after the test has been accomplished. This is contemplated to be a magnetic stripe with the information the reader needs.
  • At the left end, as shown in FIGS. 1 and 2, is [0022] sample pad 17, through which an analyte-containing sample solution 20 is administered to the porous membrane, with analytes 20A shown in the sample pad. The sample pad may also include conjugate pad 19 which is in communication with the porous membrane. Within the conjugate pad are superparamagnetic beads or particles which are coupled with antibodies, the combination of a bead and an antibody being referred to as a conjugate, a plurality of them being labeled with reference numeral 20B. These conjugates are configured to combine with target analytes in the sample solution in a known manner to create a sandwich assay, well known in the art, where the beads provide labels for the target analytes. Competitive assay techniques, also well known in the art, could also be employed.
  • The porous membrane will, as a feature of some embodiments, have a [0023] wicking pad 18 at the opposite, or right, end of the test strip. This is a conventional element.
  • The operation of the lateral flow assay is well known. The labeled analytes (in a sandwich assay, for example) move by capillary action from the left to the right as seen in FIG. 1. Labeled analytes are captured in the capture zone where reading of the assay results is accomplished. Wicking [0024] pad 18 enhances capillary flow in the porous membrane by “pulling,” or “driving” the fluid through the porous membrane. A typical material from which the porous membrane is made is nitrocellulose.
  • While the capillary action and the existence of a capture zone are well known and conventional, the manner in which the described embodiments of the invention detect the presence and the quantity of the target analytes differs greatly from the prior art. The known lateral flow assays depend upon color or fluorescence to provide a visual or optical indication of the presence of target analytes in the capture zone, but the ability of optical techniques to detect the presence of the target analytes is limited. A relatively low concentration of target analytes in the sample can result in so few captured analytes as to be optically undetectable on the surface of the porous membrane at the capture zone. Further, the optical intensity of the capture zone with the captured analytes is only a rough function of the quantity of target analytes captured. However, there is no way to accurately measure the total quantity of captured analytes within the capture zone because only the surface is optically readable. [0025]
  • The present embodiment provides greatly enhanced sensitivity and quantitative accuracy because the magnetic labeled analytes in the capture zone are detectable by a suitable magnetic detector to the extent of the target analytes within the entire volume of the capture zone. [0026]
  • Additional features may be added, including additional capture zones [0027] 14 (two are shown in FIGS. 3 and 5) and additional calibration lines 16. In FIGS. 3-5 there are four calibration lines, one before and one after each capture zone. There could be several capture zones and equivalent calibration lines.
  • A significant aspect of an embodiment of the invention is the means and manner of magnetically reading the assay. A [0028] magnetic reader 21 of the type contemplated is shown in FIG. 6. This employs the technology disclosed in PCT publication WO 99/27369, to determine the presence of target analytes and their quantity. The reader of the present invention is contemplated to be portable, that is, approximately pocket size, so that it is easily employed in the field. It will provide accurate assay readings even under stressful conditions and in poor light. The apparatus of FIG. 6 has a narrow slit opening 22 into which an assay strip can be inserted for reading by electromagnetic means. The analyte quantity may be shown in window 23, which could be an LED or an LCD screen, for example. The manner in which the capture zone with analytes bonded therein is read is shown schematically in FIG. 7. Lower electromagnetic head 31 has a top surface 32 on which is mounted detection coil 34 and across which strip 13/15 is positioned with capture zone 14 centered over the detection coil. The strip is shown in this example with surface or cover 15 of the strip actually touching the surface of the detection coil. Cover 15 thus protects the delicate structure of the porous membrane during the reading process, as well as long term if the strip is archived. Top magnet 33 is closely adjacent to the opposite side of the strip, having stripping layer 12 thereon. The structure of the electromagnetic head shown in FIG. 7 is generally equivalent to that in reader 21.
  • To enable the reader of FIG. 6 to be employed to read the analytes in the capture zone, the test strip is made readily removable from [0029] support membrane 11, and from sample pad 17 and wicking pad 18. As seen in FIGS. 3-5, pull tab 24 is secured to cover 15, which is, in turn, secured to porous membrane 13. The porous membrane is removably secured to the support by means of a removable backing 12 membrane and secured to the bottom of the porous membrane. It will be noted that the assay is essentially inverted as shown here. The sample could be applied to sample pad 17 with the strip turned over from the position of FIGS. 3 and 5. The conjugate pad 19 and the wicking pad 18 are positioned between support membrane 11 and the peelable strip 12, 13, 15. Element 11A may be a non-active polymer fill membrane. Sheet or adhesive 12 is readily removable from the surfaces of elements 18, 19 and 11A.
  • It is contemplated that the test strip, primarily consisting of the porous membrane and protective surfaces thereof, may be made sufficiently rigid to not need a support membrane. Such a configuration would not need to be stripped from anything. The reader apparatus might have to be modified somewhat to handle the different configuration of the test strip, but the principle of magnetic reading shown in FIG. 7 still applies. [0030]
  • FIG. 5 shows how the test strip, comprised of the cover, porous membrane and removable backing, is removed from the support membrane. In actuality, this removed test strip is typically about 3-12 mm wide, and only about 150-500μ thick. This strip is easily fed into [0031] reader 21 for a digital readout, which may be shown on the screen or printed on paper in any desired form by reader 21. The exposed test strip is stable and can be archived either before or after being read. Since the superparamagnetic beads are magnetized only during the reading process, the exposed test strip is not subject to degradation. The analytes contained in the capture zone remain there, labeled with the conjugate combination.
  • Alternative features of the embodiment discussed above contemplate the test strip being slid off the support membrane or peeled off, either manner of removable being physically possible. [0032]
  • The opaque surface or cover [0033] 15 has several positive functions. Contrary to prior art optical lateral flow assays, where very faint lines can easily be misinterpreted in the field, especially in stressful situations or low light conditions, there is no possibility of misinterpretation of test results with this invention. Optically read assays, especially those visually read, are also subject to operator bias. In the present invention the reader reads the total number of labeled analytes in the capture zone without inherent sources of error as mentioned above. Further, the thickness of the opaque cover precisely positions the porous membrane and thus, the capture zone, with respect to the magnet head and detection coil 34. Since the test strip actually touches the detection coil, without the protective surface the porous nitrocellulose membrane would be damaged by rubbing across detection coil 34, thereby possibly producing incorrect or unreliable readings, or both. Although being very thin, in the range of 30-50μ the cover protects against physical damage and environmental contamination as well as providing precise positioning for accurate electromagnetic readings.
  • While the present invention has been illustrated and described by means of a specific embodiment, it is to be understood that numerous changes and modifications can be made therein without departing from the scope of the claims and equivalents thereto. [0034]

Claims (16)

What is claimed is:
1. A lateral flow assay device for quantitative detection of target analytes in a sample, said device comprising:
an assay support member having a first end and a second end;
a sample receiving element at one end of said support member for introduction of the sample to be analyzed to said device; and
an immunoassay test strip comprising:
a porous analytical membrane removably mounted adjacent to and generally parallel with said support member, said analytical membrane having a first end and a second end;
at least one capture region in said analytical membrane intermediate said first and second ends thereof, said at least one capture region being configured to capture labeled analytes moving from said first end of said analytical membrane toward said second end of said analytical membrane; and
a backing member between said analytical membrane and said support member to facilitate emoval of said analytical membrane from said support member for reading the assay and for archiving said test strip.
2. The device recited in claim 1, and further comprising a protective membrane covering said analytical membrane on the side opposite to said support member, said protective membrane being optically non-transparent.
3. The device recited in claim 2, wherein said protective membrane is formed integrally with said porous membrane.
4. The device recited in claim 2, wherein said protective membrane is formed pursuant to a surface treatment of said porous membrane.
5. The device recited in claim 1, and further comprising a control region in said porous membrane for collection of magnetic conjugates that have passed the capture region to show that said test strip has been used.
6. The device recited in claim 2, and further comprising at least one magnetic calibration line printed on said protective membrane.
7. The device recited in claim 2, wherein said protective membrane is formed of material selected from the group consisting of plastic, glass and paper.
8. The device recited in claim 1, and further comprising superparamagnetic conjugate particles in said sample receiving element, said particles being configured to bind with target analytes in the sample.
9. A lateral flow assay device for quantitative detection of target analytes in a sample, said device comprising:
an assay support member having a first end and a second end;
a sample receiving element near one end of said support member for introduction of the sample to be analyzed to said device; and
an immunoassay test strip comprising:
a porous analytical membrane removably mounted adjacent to and generally parallel with said support member, said analytical membrane having a first end and a second end;
superparamagnetic conjugate particles in said sample receiving element configured to bind with the target analytes in the sample;
a capture region in said analytical membrane intermediate to said first and second ends thereof, said capture region being configured to capture labeled analytes moving from said first end of said analytical membrane toward said second end of said analytical membrane; and
a backing member between said analytical membrane and said support member to facilitate removal of said analytical membrane from said support member for reading the assay and for archiving said test strip.
10. The device recited in claim 9, and further comprising a protective membrane covering said analytical membrane on the side opposite to said support member, said protective membrane being optically non-transparent.
11. The device recited in claim 10, wherein said protective membrane is formed integrally with said porous membrane.
12. An analytical immunoassay apparatus for quantitative detection of target analytes in a sample, said apparatus comprising:
an assay support member having a first end and a second end;
a sample receiving element near one end of said support member for introduction of the sample to be analyzed to said apparatus;
an immunoassay test strip comprising:
a porous analytical membrane removably mounted adjacent to and generally parallel with said support member, said analytical membrane having a first end and a second end;
superparamagnetic conjugate particles in said sample receiving element configured to bind with the target analytes in the sample;
a capture region in said analytical membrane intermediate to said first and second ends of said analytical membrane, said capture region being configured to capture labeled analytes moving from said first end of said analytical membrane toward said second end of said analytical membrane; and
a backing member between said analytical membrane and said support member to facilitate removal of said analytical membrane from said support member for selectively reading the assay and archiving said test strip; and
a magnetic reader device for determining the presence and quantity of magnetic conjugate particle labeled target analytes in said capture region, said reader device being shaped and configured to receive said test strip after the lateral flow process has been completed.
13. The apparatus recited in claim 12, and further comprising a protective membrane covering said analytical membrane on the side opposite to said support member, said protective membrane being optically non-transparent.
14. The apparatus recited in claim 13, wherein said protective membrane is formed integrally with said porous membrane.
15. A method for conducting a lateral flow immunoassay quantitative detection of target analytes in a sample, a method comprising:
applying the sample to one end of the porous membrane of a lateral flow test strip;
coupling superparamagnetic conjugate particles residing in the test strip at said one end, the superparamagnetic particles being treated to bind with any target analyte in the sample;
capturing the bound complexes of analyte and susperparamagnetic particles in the capture region of the porous membrane as the sample and bound complexes move through the porous membrane by capillary action;
reading the quantity of labeled analytes in the capture region; and
providing an output representative of the quantity of labeled analytes in the capture region.
16. The method recited in claim 15, and further comprising removing the test strip from the lateral flow assay device with the bound complexes remaining available to be selectively stored and sensed as to the quantity of the bound complexes in the capture region.
US10/643,632 2000-03-17 2003-08-18 Immunochromatographic assay method and apparatus Abandoned US20040053423A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/643,632 US20040053423A1 (en) 2000-03-17 2003-08-18 Immunochromatographic assay method and apparatus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/527,801 US6607922B2 (en) 2000-03-17 2000-03-17 Immunochromatographic assay method and apparatus
US10/643,632 US20040053423A1 (en) 2000-03-17 2003-08-18 Immunochromatographic assay method and apparatus

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/527,801 Continuation US6607922B2 (en) 2000-03-17 2000-03-17 Immunochromatographic assay method and apparatus

Publications (1)

Publication Number Publication Date
US20040053423A1 true US20040053423A1 (en) 2004-03-18

Family

ID=24102976

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/527,801 Expired - Lifetime US6607922B2 (en) 2000-03-17 2000-03-17 Immunochromatographic assay method and apparatus
US10/643,632 Abandoned US20040053423A1 (en) 2000-03-17 2003-08-18 Immunochromatographic assay method and apparatus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/527,801 Expired - Lifetime US6607922B2 (en) 2000-03-17 2000-03-17 Immunochromatographic assay method and apparatus

Country Status (3)

Country Link
US (2) US6607922B2 (en)
AU (1) AU2001245439A1 (en)
WO (1) WO2001071344A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022392A1 (en) * 2001-07-25 2003-01-30 Hudak Robert Thomas Specimen collection container
US20030027359A1 (en) * 2001-07-25 2003-02-06 Hudak Robert Thomas Specimen collection container
US20040132091A1 (en) * 2003-01-04 2004-07-08 Ramsey James T. Specimen collection and assay container
US20070081920A1 (en) * 2005-10-12 2007-04-12 Murphy R S Semi-disposable optoelectronic rapid diagnostic test system
US20070211965A1 (en) * 2006-03-07 2007-09-13 Helbing Rene P Hand-held diagnostic systems and methods of use thereof
GB2436616A (en) * 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
US20080112847A1 (en) * 2006-11-15 2008-05-15 Nancy Yu Chen Collecting and testing device and method of use
US20110117672A1 (en) * 2006-03-21 2011-05-19 Magnisense Technology Limited Magnetic immunochromatographic test method and device

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2365526B (en) * 2000-07-31 2003-12-03 Cambridge Life Sciences Assay apparatus for measuring the amount of an analyte in a biological or environmental sample
US20030119203A1 (en) 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
US6837171B1 (en) 2002-04-29 2005-01-04 Palmer/Snyder Furniture Company Lightweight table with unitized table top
US7018849B2 (en) * 2002-01-15 2006-03-28 Piasio Roger N Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughtout
US7323139B2 (en) * 2002-07-26 2008-01-29 Quantum Design, Inc. Accessible assay and method of use
US7285424B2 (en) 2002-08-27 2007-10-23 Kimberly-Clark Worldwide, Inc. Membrane-based assay devices
EP1565745A4 (en) * 2002-11-12 2007-06-27 Strategic Diagnostics Inc Isolation and confirmation of analytes from test devices
US7781172B2 (en) 2003-11-21 2010-08-24 Kimberly-Clark Worldwide, Inc. Method for extending the dynamic detection range of assay devices
US7247500B2 (en) 2002-12-19 2007-07-24 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in membrane-based assay devices
US7851209B2 (en) 2003-04-03 2010-12-14 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in assay devices
US20040197819A1 (en) 2003-04-03 2004-10-07 Kimberly-Clark Worldwide, Inc. Assay devices that utilize hollow particles
FR2854695B1 (en) * 2003-05-07 2006-01-21 Biomerieux Sa REACTION MODULE FOR BIOLOGICAL ANALYSIS
US20050112703A1 (en) 2003-11-21 2005-05-26 Kimberly-Clark Worldwide, Inc. Membrane-based lateral flow assay devices that utilize phosphorescent detection
US7943395B2 (en) 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US7713748B2 (en) 2003-11-21 2010-05-11 Kimberly-Clark Worldwide, Inc. Method of reducing the sensitivity of assay devices
US7943089B2 (en) 2003-12-19 2011-05-17 Kimberly-Clark Worldwide, Inc. Laminated assay devices
US8128871B2 (en) 2005-04-22 2012-03-06 Alverix, Inc. Lateral flow assay systems and methods
US7815854B2 (en) 2004-04-30 2010-10-19 Kimberly-Clark Worldwide, Inc. Electroluminescent illumination source for optical detection systems
US7796266B2 (en) 2004-04-30 2010-09-14 Kimberly-Clark Worldwide, Inc. Optical detection system using electromagnetic radiation to detect presence or quantity of analyte
US7521226B2 (en) 2004-06-30 2009-04-21 Kimberly-Clark Worldwide, Inc. One-step enzymatic and amine detection technique
US10041941B2 (en) * 2005-04-22 2018-08-07 Alverix, Inc. Assay test strips with multiple labels and reading same
US7648844B2 (en) 2005-05-02 2010-01-19 Bioscale, Inc. Method and apparatus for detection of analyte using an acoustic device
US7749445B2 (en) 2005-05-02 2010-07-06 Bioscale, Inc. Method and apparatus for analyzing bioprocess fluids
US20070020699A1 (en) * 2005-07-19 2007-01-25 Idexx Laboratories, Inc. Lateral flow assay and device using magnetic particles
CA2620079A1 (en) * 2005-08-23 2007-03-01 Paul C. Harris Multi-directional immunochromatographic assays
US20070092977A1 (en) * 2005-10-14 2007-04-26 Karl Reich Forensic test for human saliva
US7816122B2 (en) * 2005-10-18 2010-10-19 Idexx Laboratories, Inc. Lateral flow device with onboard reagents
US7547557B2 (en) * 2006-06-13 2009-06-16 Quantum Design, Inc. Directed-flow assay device
US7935538B2 (en) * 2006-12-15 2011-05-03 Kimberly-Clark Worldwide, Inc. Indicator immobilization on assay devices
US8354280B2 (en) 2007-09-06 2013-01-15 Bioscale, Inc. Reusable detection surfaces and methods of using same
US8446463B2 (en) * 2008-08-22 2013-05-21 Genprime, Inc. Apparatus, method and article to perform assays using assay strips
CN101769919B (en) * 2009-01-06 2013-01-16 深圳大学 Immuno-chromatography detection device and detection method thereof
EP2488871B1 (en) * 2009-10-16 2017-01-04 Åmic AB An assay method involving the use of magnetic particles
WO2012003617A1 (en) * 2010-07-05 2012-01-12 深圳大学 Immuno-chromatographic detection device and detection method thereof
US8815610B2 (en) * 2010-10-15 2014-08-26 International Business Machines Corporation Magnetic nanoparticle detection across a membrane
CN102353774A (en) * 2011-06-13 2012-02-15 清华大学深圳研究生院 Immunochromatographic test paper for detecting chloramphenicol and its preparation method
KR101664175B1 (en) 2011-07-12 2016-10-11 푸드체크 시스템스, 아이엔씨. Culture medium, method for culturing salmonella and e. coli and method for detecting salmonella and e. coli
US8968677B2 (en) 2013-01-22 2015-03-03 Quantum Design International, Inc. Frazil ice conjugate assay device and method
CN103308671B (en) * 2013-05-22 2016-02-03 北京康彻思坦生物技术有限公司 A kind of detection film and detection system
US9981264B2 (en) 2014-11-04 2018-05-29 Grace Bio-Labs, Inc. Nitrocellulose extrusion for porous film strips
US20180258467A1 (en) 2015-04-07 2018-09-13 Polyskope Labs Detection of one or more pathogens
CN106442972A (en) * 2016-08-31 2017-02-22 陈继营 Application of superparamagnetic nano-particles serving as marker in preparation of PJI diagnosis test paper
US10576475B2 (en) 2016-09-15 2020-03-03 Genprime, Inc. Diagnostic assay strip cassette
EP3552018A1 (en) * 2016-12-09 2019-10-16 Cellmic, LLC Diagnostic testing assays and related devices with security and methods of use thereof
CA3051475A1 (en) * 2017-01-26 2018-08-02 Vital Biosciences, Inc. Magnetic particle-based immunoassay and methods of using the same
WO2019178157A1 (en) 2018-03-16 2019-09-19 Karius, Inc. Sample series to differentiate target nucleic acids from contaminant nucleic acids
JP2021534406A (en) * 2018-08-17 2021-12-09 ユニバーシティー オブ ロチェスター Optical biosensors including disposable diagnostic membrane and permanent photonic detection device
US11634782B2 (en) 2019-03-20 2023-04-25 Hygiena, Llc Quantification of microorganisms in samples and methods of determining quantification conditions thereof
US11885800B2 (en) 2019-10-18 2024-01-30 Imra America, Inc. Method and system for detecting analyte of interest using magnetic field sensor and magnetic particles
CN113960313B (en) * 2021-12-22 2022-04-12 上海思路迪医学检验所有限公司 Exosome ALK fusion protein magnetic immunochemiluminescence detection kit

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US3981776A (en) 1967-02-16 1976-09-21 Rolf Saxholm Magnetically responsive, biologically active substance and associated methods and apparatus
ZA733612B (en) * 1972-10-11 1974-04-24 Merck Patent Gmbh Container for test strips
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US5958790A (en) 1984-12-20 1999-09-28 Nycomed Imaging As Solid phase transverse diffusion assay
CA1303983C (en) 1987-03-27 1992-06-23 Robert W. Rosenstein Solid phase assay
DE3856542T2 (en) 1987-04-27 2003-10-30 Inverness Medical Switzerland Test device for carrying out specific binding tests
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4956302A (en) 1987-09-11 1990-09-11 Abbott Laboratories Lateral flow chromatographic binding assay device
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5075078A (en) 1989-10-05 1991-12-24 Abbott Laboratories Self-performing immunochromatographic device
US5998220A (en) 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
US5869345A (en) 1991-05-29 1999-02-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing conductive barrier
JPH0792459B2 (en) 1991-06-18 1995-10-09 オリンパス光学工業株式会社 Immunological test method
US5395498A (en) 1991-11-06 1995-03-07 Gombinsky; Moshe Method for separating biological macromolecules and means therfor
US5445971A (en) 1992-03-20 1995-08-29 Abbott Laboratories Magnetically assisted binding assays using magnetically labeled binding members
US5445970A (en) 1992-03-20 1995-08-29 Abbott Laboratories Magnetically assisted binding assays using magnetically labeled binding members
DK0622119T3 (en) * 1993-04-23 2000-04-10 Roche Diagnostics Gmbh Test element storage system
FR2732116B1 (en) 1995-03-21 1997-05-09 Bio Merieux METHOD AND DEVICE FOR THE QUALITATIVE AND / OR QUANTITATIVE DETERMINATION OF AN ANALYTE, IN PARTICULAR OF A BACTERIA, IN A SAMPLE, BY MAGNETIC WAY
CA2176053C (en) 1995-05-09 1999-10-05 Yoshihiro Kinoshita Method and apparatus for agglutination immunoassay
US5656502A (en) * 1995-06-07 1997-08-12 Diagnostic Chemicals Limited Test strip holder and method of use
WO1997034150A1 (en) 1996-03-14 1997-09-18 Abbott Laboratories Binding members extending from particles for immunoassay
AU740812B2 (en) 1996-03-20 2001-11-15 Serex, Inc. Chromatographic immunoassay device and method utilizing particle valency for quantitation
US5900379A (en) * 1996-04-11 1999-05-04 Mizuho Usa, Inc. Analytical device
US5968839A (en) 1996-05-13 1999-10-19 Metrika, Inc. Method and device producing a predetermined distribution of detectable change in assays
US5798273A (en) 1996-09-25 1998-08-25 Becton Dickinson And Company Direct read lateral flow assay for small analytes
US5879951A (en) 1997-01-29 1999-03-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing unidirectional flow
US5981297A (en) 1997-02-05 1999-11-09 The United States Of America As Represented By The Secretary Of The Navy Biosensor using magnetically-detected label
US5939252A (en) 1997-05-09 1999-08-17 Lennon; Donald J. Detachable-element assay device

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022392A1 (en) * 2001-07-25 2003-01-30 Hudak Robert Thomas Specimen collection container
US20030027359A1 (en) * 2001-07-25 2003-02-06 Hudak Robert Thomas Specimen collection container
US7270959B2 (en) * 2001-07-25 2007-09-18 Oakville Hong Kong Company Limited Specimen collection container
US20040132091A1 (en) * 2003-01-04 2004-07-08 Ramsey James T. Specimen collection and assay container
US8865458B2 (en) 2003-01-04 2014-10-21 Alere Switzerland Gmbh Specimen collection and assay container
US8394626B2 (en) 2003-01-04 2013-03-12 Alere Switzerland Gmbh Specimen collection and assay container
US20100028981A1 (en) * 2003-01-04 2010-02-04 Inverness Medical Switzerland Gmbh Specimen colleciton and assay container
US20070081920A1 (en) * 2005-10-12 2007-04-12 Murphy R S Semi-disposable optoelectronic rapid diagnostic test system
US20070211965A1 (en) * 2006-03-07 2007-09-13 Helbing Rene P Hand-held diagnostic systems and methods of use thereof
US20110117672A1 (en) * 2006-03-21 2011-05-19 Magnisense Technology Limited Magnetic immunochromatographic test method and device
US9329181B2 (en) * 2006-03-21 2016-05-03 Magnisense Technology Limited Magnetic immunochromatographic test method and device
GB2436616A (en) * 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
US20080112847A1 (en) * 2006-11-15 2008-05-15 Nancy Yu Chen Collecting and testing device and method of use

Also Published As

Publication number Publication date
US20030040124A1 (en) 2003-02-27
AU2001245439A1 (en) 2001-10-03
US6607922B2 (en) 2003-08-19
WO2001071344A2 (en) 2001-09-27
WO2001071344A3 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
US6607922B2 (en) Immunochromatographic assay method and apparatus
US7323139B2 (en) Accessible assay and method of use
US11204328B2 (en) Assay reader operable to scan a test strip
US7547557B2 (en) Directed-flow assay device
CA2491102A1 (en) Assay device for liquid sample
US20080020482A1 (en) Assay Devices
EP1666879A2 (en) Read-write assay system
US20100255510A1 (en) rapid and sensitive method for quantitative determination of the level of heparin - pf4 complex induced immunoglobulin antibodies
US20120329039A1 (en) Substance determining apparatus
WO1996005326A1 (en) Method and apparatus for magnetically detecting proteins and nucleic acids
CN203561636U (en) Directional flow immunochromatography device

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION